Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

2018 ◽  
Vol 19 (9) ◽  
pp. 1215-1228 ◽  
Author(s):  
Paula Cramer ◽  
Julia von Tresckow ◽  
Jasmin Bahlo ◽  
Sandra Robrecht ◽  
Petra Langerbeins ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Primary Endpoint ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase

scholarly journals Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

2018 ◽  
Vol 5 (4) ◽  
pp. e170-e180 ◽  
Author(s):  
Jennifer R Brown ◽  
Mehdi Hamadani ◽  
John Hayslip ◽  
Ann Janssens ◽  
Nina Wagner-Johnston ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Hodgkin Lymphoma ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Open Label Phase

scholarly journals Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

2018 ◽  
Vol 19 (1) ◽  
pp. 65-75 ◽  
Author(s):  
Jeffrey A Jones ◽  
Anthony R Mato ◽  
William G Wierda ◽  
Matthew S Davids ◽  
Michael Choi ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Interim Analysis ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

2016 ◽  
Vol 17 (6) ◽  
pp. 768-778 ◽  
Author(s):  
Stephan Stilgenbauer ◽  
Barbara Eichhorst ◽  
Johannes Schetelig ◽  
Steven Coutre ◽  
John F Seymour ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document